J and J Vaccines for Covid
Johnson and Johnson has developed a new Covid 19 vaccine that is easier to use and administer and has strong efficacy. It is expected to be approved for emergency use at the end of the week, but not be widely available in quantity until this April.
The efficacy findings were 72% in the US, 66% in Latin America and 57% in South Africa. There were no deaths, no hospitalizations or anaphylactic shocks associated with those who took the vaccine. It is 85% effective against severe disease. It seemed to be less effective for people 60 or older with comorbidities like diabetes.
The advantages of the J and J vaccine are that it is only one dose and can be shipped and stored at temperatures between 36 and 46 degrees.